Q1FY27 results: Revenue up 13%, PAT up 29%

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-3.8%Reaction day

₹2569.90

prior close

₹2604.00

announcement price

After-mkt

timing

Nifty Midcap 150market+0.5%-4.3% vs market

Pharmaceuticals peers, median of 164sector+0.1%-3.9% vs sector

On the reaction day the stock moved 4.3 pts less than Nifty Midcap 150 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-5.2

10m

-5.8

15m

-5.1

30m

-5.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-3.8+0.5-4.3+0.1-3.9

Next day

-3.4+1.7-5.1+1.1-4.5

-4.5+1.4-5.8+1.0-5.5

-5.1+1.6-6.7+1.1-6.2

-5.8+1.2-7.0+1.2-7.0

-4.5+1.4-5.9+1.5-6.0

-5.5+1.9-7.4+2.3-7.8

15d

-7.2+1.6-8.9+1.3-8.6

-5.9+2.2-8.1+2.3-8.2

-2.6-5.1+2.5+3.2-5.7

—————

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma posted Q1FY27 consolidated revenue of INR 4,031 Cr, up 12.9% YoY. Domestic business grew 10.5% and exports surged 29%. EBITDA rose 24.7% to INR 1,060 Cr with margins expanding 250 bps to 26.3%. PAT grew 29.1% to INR 574 Cr. Strong show in Cardiac (19.4%), Anti-Diabetes (12.7%), and specialty brands. Diluted EPS at INR 13.7, up 29.6%.

Likely market impact

Broad-based growth with sharp margin expansion signals strong business momentum and pricing power.